---
title: "Jincheng Pharm released its performance for the first half of the year, with a net profit attributable to the parent company of 43.3832 million yuan, a year-on-year decrease of 66.78%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253828976.md"
description: "Jincheng Pharm released its semi-annual report for 2025, reporting an operating income of 1.36 billion yuan, a year-on-year decrease of 22.65%; net profit attributable to shareholders was 43.3832 million yuan, a year-on-year decrease of 66.78%; net profit excluding non-recurring gains and losses was 38.7305 million yuan, a year-on-year decrease of 68.12%; basic earnings per share were 0.11 yuan"
datetime: "2025-08-20T13:10:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253828976.md)
  - [en](https://longbridge.com/en/news/253828976.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253828976.md)
---

# Jincheng Pharm released its performance for the first half of the year, with a net profit attributable to the parent company of 43.3832 million yuan, a year-on-year decrease of 66.78%

According to the Zhitong Finance APP, Jincheng Pharm (300233.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 1.36 billion yuan, a year-on-year decrease of 22.65%. The net profit attributable to shareholders of the listed company was 43.3832 million yuan, a year-on-year decrease of 66.78%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 38.7305 million yuan, a year-on-year decrease of 68.12%. The basic earnings per share were 0.11 yuan

### Related Stocks

- [300233.CN](https://longbridge.com/en/quote/300233.CN.md)

## Related News & Research

- [Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus](https://longbridge.com/en/news/287162474.md)
- [20:38 ETHyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"](https://longbridge.com/en/news/287135394.md)
- [HSA warns public against consuming herbal remedy containing potent steroid](https://longbridge.com/en/news/287022845.md)
- [Zunder launches charging infrastructure software Kawat for third parties](https://longbridge.com/en/news/287080731.md)
- [US working with small biotech firm on experimental Ebola treatment, Bloomberg News reports](https://longbridge.com/en/news/287108072.md)